Skip to main content

Leukaemia: Drugs

Volume 506: debated on Thursday 4 March 2010

To ask the Secretary of State for Health when he expects to receive the National Institute for Health and Clinical Excellence's recommendations on the use of dasatinib and nilotinib for chronic myeloid leukaemia patients. (319180)

I understand that the National Institute for Health and Clinical Excellence (NICE) currently expects to issue final guidance to the NHS on the use of dasatinib and nilotinib for the treatment of imatinib-intolerant chronic myeloid leukaemia (CML) in June 2010. Details of this appraisal are available on NICE'S website at:

http://guidance.nice.org.uk/TA/Wavel7/18

NICE will schedule the technology appraisal of dasatinib and nilotinib for the treatment of imatinib-resistant CML into the review of its published guidance on the use of imatinib for the treatment of CML.

To ask the Secretary of State for Health how many people with chronic myeloid leukaemia have been prescribed (a) dasatinib and (b) nilotinib in the last 12 months. (319181)

Information is not collected centrally on the number of people prescribed drugs or for what purpose drugs are prescribed.

In the period October 2008 to September 2009, the latest 12 months available, there were 109 prescriptions for dasatinib and less than 100 for nilotinib written in the United Kingdom and dispensed in the community in England.

Information for hospital prescribing is not available.